Clinical trial
A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas.
NCT00062504 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas.
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 31, 2003
- Completion date
- April 30, 2006
- Enrollment
- 30 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic astrocytoma, anaplastic mixed oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma multiforme